| Popis: |
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) -- OCT 25-28, 2017 -- Paris, FRANCE Ziemssen, Tjalf/0000-0001-8799-8202; McCombe, Pamela/0000-0003-2704-8517; Ramo-Tello, Cristina M/0000-0001-8643-5053; Lugaresi, Alessandra/0000-0003-2902-5589; Ferraro, Diana/0000-0003-4818-3806; WOS: 000413730200044 … European Comm Treatment & Res Multiple Sclerosis, Americas Comm Treatment & Res Multiple Sclerosis BiogenBiogen; MerckMerck & Company; Teva; NovartisNovartis; Charles University in Prague [PRVOUK-P26/LF1/4]; Czech Ministry of HealthMinistry of Health, Czech Republic [NT13237-4/2012]; Actelion; Celgene; RocheRoche Holding; SanofiSanofi-Aventis; Czech Ministry of EducationMinistry of Education, Youth & Sports - Czech Republic [Q27/LF1]; Biogen-IdecBiogen; Teva Canada Innovation; Genzyme SanofiGenzyme Corporation; EMD; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Bayer ScheringBayer AG; GenzymeGenzyme Corporation; Novartis Pharma; Sanofi-Genzyme; Sanofi AventisSanofi-Aventis; UCBUCB Pharma SA; LundbeckLundbeck Corporation; Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche; Almirall; BayerBayer AG; Dystonia Ireland; Health Research Board of Ireland; European Dystonia Foundation; GlaxoSmithKlineGlaxoSmithKline; CIHRCanadian Institutes of Health Research (CIHR); MS Society of Canada; Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi Multipla (FISM); Teva-Neuroscience; Canadian Multiple sclerosis society; Teva Neurosciences; Mitsubishi; ONO Pharmaceuticals Dana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague (PRVOUK-P26/LF1/4 and Czech Ministry of Health (NT13237-4/2012).; Eva Havrdova received speaker honoraria and consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva, and support for research activities from Czech Ministry of Education, project Progres Q27/LF1.; Maria Trojano received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva, Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis.; Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD. He has also received a research grant from Canadian Institutes of Health Research.; Vincent Van Pesch received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma and Bayer Schering.; Diana Ferraro received travel grants and/or speaker honoraria from Merck, TEVA, Novartis, Biogen and Sanofi-Genzyme.; Eugenio Pucci served on scientific advisory boards for Merck, Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, UCB, Lundbeck, Novartis, Bayer Schering, Biogen, Merck, Genzyme and Teva; he has received travel grants and equipment from "Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche".; Cristina Ramo-Tello received research funding, compensation for travel or speaker honoraria from Biogen, Novartis, Genzyme and Almirall.; Norma Deri received funding from Bayer, Merck, Biogen, Genzyme and Novartis.; Michael Hutchinson served on a medical advisory board for the CONFIRM study (BG00012) for Biogen; has received speaker's honoraria from Novartis, Biogen, and Bayer Schering; and receives research support from Dystonia Ireland, the Health Research Board of Ireland, and the European Dystonia Foundation.; Tjalf Ziemssen reports grants from Novartis; grants and personal fees from Bayer, Biogen, Teva, Genzyme, and Novartis; and personal fees from Merck, Almirall, GlaxoSmithKline, and Roche.; Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.; Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institution received research grants from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM).; Pierre Grammond is a Merck, Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis.; Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals. |
